Below are a graph and a table of the effect of Ferring’s degarelix on testosterone compared with the effect of Lupron. On December 24th Ferring announced that FDA has approved degarelix for the treatment of hormonally sensitive advanced prostate cancer.

Degarelix (generic name) is a GnRH receptor antagonist. The company says: “Degarelix achieves medical castration differently than LHRH agonists, specifically by binding reversibly to GnRH receptors on cells in the pituitary gland, quickly reducing the release of gonadotropins and consequently testosterone.” How quickly? Like this :

Degarelix versus Lupron Effect: Percent drop in Testosterone drop over 28 days